• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Society of Cardiology (ESC) Congress - 2025

August 29 - September 1, 2025

  1. Farxiga (dapagliflozin)
  2. Chronic Kindey Disease
  3. Dyslipidemia
  4. Hypertension
  5. Heart Failure/Chronic Kidney Disease
  6. Heart Failure
  7. Wainua (eplontersen)
  8. ATTR Amyloidosis
  9. Type 2 Diabetes
  10. Major bleeding
  11. Lokelma (Sodium zirconium cyclosilicate)

html

Sequencing in over 120,000 cases unveils the rare coding variant architecture of atrial fibrillation

html

A value-based analysis of the systematic use of dapagliflozin in patients with heart failure

html

EVOLUTION-HF DEallEF: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: results of 1st interim analysis

html

Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure

html

Leveraging AI and clinical guidelines to identify undiagnosed and under-treated CKD patients for treatment optimisation

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

html

Chronic kidney disease in patients with heart failure in German primary care practices: the InspeCKD study

PDF

Laroprovstat (AZD0780), a novel, oral PCSK9 inhibitor with properties allowing for broad use,food-intake independency and co-administration with other lipid-lowering therapies

html

BaxHTN - Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

html

High prevalence of aldosterone dysregulation in hypertensive adults tested for aldosterone and renin levels

PDF

Risk of cardiorenal and metabolic outcomes in inadequately controlled hypertension: insights from the ENLIGHTN study

PDF

Outcomes of aldosterone dysregulation in routine clinical care ADEL (Aldosterone Dysregulation Epidemiology Landscape) – a population-based study

PDF

Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

html

Development and implementation of a heart failure dashboard for England: nationwide analysis of 1.4 million primary and secondary health care records

html

WATCH HF Awareness of prevalence, diagnosis and treatment of chronic heart failure in at risk patients in german primary care analysing real world data of chronic HF management in Germany

html

Unveiling gaps in heart failure management in Germany: a retrospective analysis of national data and healthcare utilisation patterns

html

Heart failure prevalence, medication prescription rates, and adverse outcomes in patients undergoing TAVI: the real-world data analysis

pdf

Atrial structure and function in patients with amyloidosis: findings from the NEURO-TTRansform study

PDF

Early Symptoms and Medical History of Patients with Transthyretin Amyloidosis Cardiomyopathy: Results from the Multi-Country OverTTuRe Study

html

The incidence of death and risk factors for mortality in cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records

html

OverTTuRe study: disease burden at diagnosis in ATTR amyloidosis patients with cardiac impairment in Spain

pdf

MaesTTRo: Initial findings from a pioneering prospective multi-country real-world study of patients with transthyretin amyloidosis

html

The impact of microalbuminuria and proteinuria on cardiovascular outcomes in individuals with type 2 diabetes mellitus: a population-based, electronic health records study

html

Factor Xa inhibitor associated major bleeding characteristics, burden, and health resource utilization in Alberta, Canada - an observational population based study

html

Hyperkalaemia in patients with heart failure in German general practices: prevalence, diagnosis and treatment: The WATCH-K study

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2025 AstraZeneca. All rights reserved.

US-69609; US-91816; US-103094; US-106788

Last Updated 11/25

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Privacy Notice

Legal Notice

Cookie Preferences

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Pharma Logo

Privacy NoticeLegal NoticeCookie Preferences